Analysts Set Hologic, Inc. (NASDAQ:HOLX) Price Target at $80.15

Hologic, Inc. (NASDAQ:HOLX) has been assigned a consensus recommendation of “Moderate Buy” from the eighteen ratings firms that are covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $80.1538.

Several brokerages recently weighed in on HOLX. Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Evercore ISI set a $78.00 price objective on shares of Hologic and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Morgan Stanley lifted their price objective on shares of Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 31st. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Wall Street Zen lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, October 1st.

Hologic Trading Up 2.9%

Shares of HOLX opened at $71.87 on Friday. The company’s fifty day moving average is $67.19 and its 200 day moving average is $63.62. Hologic has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The stock has a market capitalization of $15.99 billion, a PE ratio of 29.82, a P/E/G ratio of 2.40 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the previous year, the business posted $1.06 earnings per share. Hologic’s quarterly revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Sell-side analysts expect that Hologic will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.88% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its stake in shares of Hologic by 294.3% during the second quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock valued at $718,223,000 after purchasing an additional 8,227,318 shares during the period. Invesco Ltd. boosted its stake in shares of Hologic by 72.5% during the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after purchasing an additional 3,505,828 shares during the period. Norges Bank purchased a new stake in shares of Hologic during the second quarter valued at $180,055,000. Victory Capital Management Inc. boosted its stake in shares of Hologic by 34.4% during the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock valued at $408,283,000 after purchasing an additional 1,692,177 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Hologic by 473.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock valued at $111,180,000 after purchasing an additional 1,405,085 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.